Frontage, a full-service CRO located in the U.S. and China, has expanded its bioanalytical laboratories to meet increased demand for its services from existing and new biopharmaceutical clients.

As a provider of bioanalytical services for small molecules, large molecules and biologics, including the bioanalysis of Antibody Drug Conjugates (ADCs) by Mass Spectroscopy and Ligand Binding platforms, Frontage has completed an expansion of its operations in Exton, Pa. With an additional 10,000 square feet of laboratories, the expansion allows for the installation of 20 more state-of-the-art mass spectrometers. The company also added laboratories that expand its biologics service offerings for ECL and ELISA-based assays, and its growing DMPK operations supporting discovery-stage pharmacokinetics and development-stage metabolism studies.

Frontage has hired 21 additional scientific personnel, including eight Ph.D. chemists. With new equipment, lab space and scientific team members, Frontage is continuing its efforts to improve client satisfaction and turn-around times for method development, validation and analysis of regulated bioanalytical samples with an increased capacity of 50,000 samples per month.